fda and glp-1 The New York Times spotlighted MEDVi. The had already warned the self-proclaimed 'fastest growing company in history.' Readout Newsletter: FDA GLP-1 labels,

Clinical Evidence: GLP-1s and Sperm Health Recent research from the AUA 2025 study 3 provides compelling evidence that GLP-1 receptor agonists (GLP-1 RAs), like semaglutide, have a significant connection in improving sperm count in overweight and obese men

Analysts forecast that the obesity drug market will be worth $100 billion by 2030

49 The semaglutide development process shows that the lipidation approach is decisive to the selectivity of the protein

All data were analyzed using Prism GraphPad 9 or Stata/SE 14.2

Specific considerations for menopausal women: Interaction with hormone replacement therapy (HRT) appears minimal, though absorption of oral medications may be affected by delayed gastric emptying Tirzepatide may reduce oral contraceptive effectiveness

Insurance coverage for tirzepatide is limited and often requires extensive documentation, prior authorizations, and step therapy failures before approval